Rutgers New Jersey Medical School has rolled out routine blood tests for the cardiovascular biomarker at another one of its ...

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.

The firms are planning two clinical trials of the anti-CTLA-4 agent muzastotug in colorectal cancer and in solid tumors.

As part of the deal, AbbVie will acquire Capstan's targeted LNP platform technology and its lead candidate for B cell-mediated autoimmune diseases.

The firm is advancing its AI-driven multi-modal digital pathology platform as a tool for guiding clinical trial design and patient identification.

The approval in the second-line EGFR- and MET-altered setting was based on results from the SACHI trial, which compared Orpathys and Tagrisso against chemo.

The company is developing treatments for autism and substance use disorders tailored to patient subgroups identified by clinico-genomic signatures.

For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

The firm will take a different reimbursement strategy for the test than its prior owner Biocept, which stopped selling it after filing for bankruptcy in 2023.

NEW YORK – Politicians and healthcare administrators in Washington have recently spoken out against direct-to-consumer pharmaceutical advertising, but experts say the latest legislative attempt to ban ...

NEW YORK – Bristol Myers Squibb on Friday said the US Food and Drug Administration approved label updates for its autologous CAR T-cell therapies Breyanzi (lisocabtagene maraleucel) and Abecma ...